Assays for Evaluation of Minimal Residal Disease (MRD)
PentaBase offers assays for evaluation of minimal residual disease (MRD) that are both off the shelf as well as customised to less frequent patient-specific mutations. Customised assays are designed and produced on demand to allow for rapid initiation of monitoring of treatment efficiency and disease progression.
Fast Development Service for MRD Assays
Monitoring of treatment efficiency and disease progression using patient-specific genetic biomarkers offers great potential to improve overall survival of cancer patients. We are offering as a service to design and produce customised highly sensitive PCR assays targeting patient-specific cancer mutations. Our customised MRD assays are based on our INA®-technology allowing for detection of down to a few molecules of single nucleotide variants from liquid biopsies.
